Logo of Immutep (ASX:IMM)Latest Immutep (ASX:IMM) News

Page 1
Page 1 of 4

Market Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Explorers led the strongest gains, while biotech, payments and gold producers suffered the biggest falls. Takeover bids, project funding and trial results drove sharp moves across the market.

Resources stayed busy, but investors punished companies with weak cash positions, delayed approvals or disappointing operating updates.
Logan Eniac
31 Oct 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Immutep shifts efti strategy after manufacturing differences surface in failed trial

Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
29 Oct 2026

Immutep’s FY26 loss widens as failed lung cancer trial reshapes the pipeline

Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
27 Oct 2026

Immutep’s failed Phase III trial leaves manufacturing questions and a shorter cash runway

Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
26 Oct 2026

Market Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Rare earths, scandium and biotech stocks led the week’s gains, while a rights issue sent Green & Gold Minerals sharply lower. Large capital raisings, mine funding and takeover activity kept resources at the centre of investor attention.
Logan Eniac
12 Sept 2026

Healthcare Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Neurizon and Clever Culture Systems led the week with 35.71% gains, while CONNEQT also rose despite giving back part of its reopening move.
Biotech trial funding, device manufacturing and healthcare launches shaped investor decisions across the sector.
Logan Eniac
12 Sept 2026

Immutep Pins Efti Reset on Manufacturing Differences After TACTI-004 Failure

Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.
Ada Torres
11 Sept 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Immutep Reports Mature 30.9-Month Survival in 1L NSCLC but TACTI-004 Trial Halted

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.
Ada Torres
13 July 2026

Market Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Speculative growth names and biotech drove the biggest gains this week, while one consumer staple copped the heaviest selling after cutting guidance. Deal flow stayed busy, but investors were even more responsive to hard numbers: profit upgrades, feasibility studies, contract wins and fresh drilling results.
Logan Eniac
18 Apr 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026